Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Kezar Life Sciences Inc.

    NASDAQ: KZR · Real-Time Price · USD
    4.23
    -0.11 (-2.53%)
    At close: Jun 17, 2025, 10:37 AM
    -2.53%
    Bid 4.1
    Market Cap 30.9M
    Revenue (ttm) n/a
    Net Income (ttm) -78.63M
    EPS (ttm) -10.78
    PE Ratio (ttm) -0.39
    Forward PE -0.72
    Analyst Hold
    Ask 4.32
    Volume 22,806
    Avg. Volume (20D) 30,977
    Open 4.25
    Previous Close 4.34
    Day's Range 4.03 - 4.25
    52-Week Range 3.62 - 9.20
    Beta 0.57

    About KZR

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol KZR
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for KZR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    8 months ago
    +42.1%
    Kezar Life Sciences shares are trading higher afte... Unlock content with Pro Subscription
    news image

    2 weeks ago · businesswire.com

    Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

    news image

    3 weeks ago · zacks.com

    Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

    Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    1 month ago · businesswire.com

    Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

    news image

    2 months ago · seekingalpha.com

    Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)

    Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & C...

    news image

    2 months ago · businesswire.com

    Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

    news image

    2 months ago · businesswire.com

    Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

    SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun...

    Add to Watchlist